Wyeth LLC v. AstraZeneca (Fed. Cir., July 9, 2026) 2024-2325
This episode concerns a Federal Circuit decision affirming that several of Wyeth’s cancer treatment patents are invalid due to a lack of enablement. Although a jury originally awarded Wyeth over $100 million in damages for infringement by AstraZeneca, the district court overturned the verdict because the patents failed to provide enough guidance for a specialist to determine a functional unit dosage. The court found that the patent specifications relied on broad, projected ranges and internal laboratory data that did not translate safely to human patients. Furthermore, testimony revealed that…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.